What is the current Price Target for the Relmada Therapeutics Inc stock?

The average Relmada Therapeutics Inc target price is $1.02. This is 79.51% higher than the current stock price. The highest price target is 84.79%, the lowest is 6.65%. 5 Analysts have issued a price target Relmada Therapeutics Inc 2026 .

How high will the Relmada Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Relmada Therapeutics Inc stock will rise. The performance of stocks, including the Relmada Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Relmada Therapeutics Inc stock today?

The performance of Relmada Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Relmada Therapeutics Inc stock fall?

The decline in Relmada Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Relmada Therapeutics Inc Forecast, price target & analysts

$0.57

3.37% yesterday

Nasdaq, Aug 13, 10:00 pm CET

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Relmada Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Relmada Therapeutics Inc Classifications & Recommendation:

Hold

57%

Sell

43%

Relmada Therapeutics Inc Price Target

Target Price	$1.02
Price	$0.57
Potential	79.51% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Relmada Therapeutics Inc 2026 . The average Relmada Therapeutics Inc target price is $1.02. This is 79.51% register free of charge higher than the current stock price. The highest price target is $1.05 84.79% register free of charge , the lowest is $0.61 6.65% register free of charge .
	A rating was issued by 7 analysts: 0 Analysts recommend Relmada Therapeutics Inc to buy, 4 to hold and 3 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Relmada Therapeutics Inc stock has an average upside potential 2026 of 79.51% register free of charge . Most analysts recommend the Relmada Therapeutics Inc stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.65	-1.97
	19.21%	25.66%
P/E		negative

3 Analysts have issued a Relmada Therapeutics Inc forecast for earnings per share. The average Relmada Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.65	19.21%
2025	$-1.97 25.66% Unlock
2026	$-1.73 12.18% Unlock
2027	$-1.56 9.83% Unlock
2028	$-0.79 49.36% Unlock
2029	$-0.71 10.13% Unlock
2030	$-0.68 4.23% Unlock

Current	-0.23	71.54%
2025	-0.30 27.55% Unlock
2026	-0.34 13.33% Unlock
2027	-0.38 11.76% Unlock
2028	-0.75 97.37% Unlock
2029	-0.82 9.33% Unlock
2030	-0.86 4.88% Unlock

Relmada Therapeutics Inc...

Current Relmada Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Mizuho	Locked ➜ Locked	Locked	Dec 05 2024
Leerink Partners	Locked ➜ Locked	Locked	Dec 04 2024
Jefferies	Locked ➜ Locked	Locked	Sep 17 2024

Analyst Rating	Date
Locked Mizuho: Locked ➜ Locked	Dec 05 2024
Locked Leerink Partners: Locked ➜ Locked	Dec 04 2024
Locked Jefferies: Locked ➜ Locked	Sep 17 2024

Discover more stocks with a high price target

Deutsche Telekom 27.63%

TUI 25.18%

BioNTech SE - ADR 24.36%

Microsoft 22.46%

Alibaba Group Holding Ltd 22.32%

Snowflake 19.16%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now